Molina Healthcare, Inc. MOH is aided by a growing Medicaid and Medicare customer base, contract wins, acquisitions and a ...

Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

January 05, 2025, 00:04 am ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Becomes the first subcutaneously administered PD-1 inhibitor.

VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was ...

Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...

Principal Financial Group Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 25.7 ...